Uridine (Synonyms: NSC 20256, 1-β-D-Ribofuranosyluracil, Uracil-1-β-D-ribofuranoside, β-Uridine) |
Catalog No.GC13742
One-Click Copy Product Info
|
Uridine is a nucleoside that contains uracil and is linked to the ribose ring through a β-N1-glycosidic bond.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 58-96-8
Sample solution is provided at 25 µL, 10mM.
Uridine is a nucleoside that contains uracil and is linked to the ribose ring through a β-N1-glycosidic bond [1]. Uridine regulates enzymes and intermediates in the Uridine metabolism (such as UTP, DHODH, and UPase) and is associated with glucose homeostasis, lipid metabolism, and amino acid metabolism [2-3].
In vitro, Uridine (6-24mM; 7 days) dose-dependently inhibits the proliferation of leukemia cells HL-60 and induces HL-60 to differentiate into mature cells with monocyte and granulocyte characteristics [1]. Uridine (0.2-0.4mg/mL; 10h) reduces hepatocyte apoptosis caused by CCl4, significantly reduces the expression of Caspase-3 and Bax, and upregulates Bcl-2 expression [4].
In vivo, Uridine (10-20mg/kg; oral; 6 weeks) alleviates liver fibrosis in mice with CCl4-induced liver fibrosis model and inhibits the expression of pro-inflammatory cytokines and the activation of the NF-κB signaling pathway [4]. Uridine (30mg/kg; iv; single dose) significantly increases the UDP and UTP contents in the myocardium of rats with acute myocardial ischemia (AMI) and ischemia/reperfusion injury (I/R), reduces CrP and ATP levels, and significantly reduces the size of the ischemic area in the myocardium [5].
References:
[1] Sokoloski JA, et al., Effects of uridine on the growth and differentiation of HL-60 leukemia cells. Leuk Res. 1991;15(11):1051-8.
[2] Zhang Y, Guo S, Xie C, et al. Uridine metabolism and its role in glucose, lipid, and amino acid homeostasis[J]. BioMed research international, 2020, 2020(1): 7091718.
[3] Chenna Narendra S, Chalise J P, Magnusson M, et al. Local but not systemic administration of uridine prevents development of antigen-induced arthritis[J]. PloS one, 2015, 10(10): e0141863.
[4] Zheng W V, Li Y, Cheng X, et al. Uridine alleviates carbon tetrachloride‐induced liver fibrosis by regulating the activity of liver‐related cells[J]. Journal of Cellular and Molecular Medicine, 2022, 26(3): 840-854.
[5] Krylova IB, Selina EN, Bulion VV, et al. Uridine treatment prevents myocardial injury in rat models of acute ischemia and ischemia/reperfusion by activating the mitochondrial ATP-dependent potassium channel. Sci Rep. 2021;11(1):16999.
| Cell experiment [1]: | |
Cell lines | AML12 cells |
Preparation Method | To avoid the adverse effects of hepatocyte injury produced during perfusion, the mouse hepatocyte cell line (AML12, the mouse hepatocyte cell line) was also used to check the protective effects of Uridine on hepatocytes apoptosis caused by CCl4. Before 4h prior to treatment with 10mmol/L CCl4 for 10h, the hepatocytes were treated with Uridine (200µg/ml) or the vehicle (DMSO). Cell apoptosis rate was assessed using a PE Annexin V apoptosis detection kit according to the manufacturer's instructions. The cell samples were analysed with a FACSCalibur flow cytometer (Becton-Dickinson), and cells that are viable are Annexin V-PE and 7-AAD negative; cells that are in early apoptosis are Annexin V-PE positive and 7-AAD negative; and cells that are in late apoptosis or already dead are both Annexin V-PE and 7-AAD positive. |
Reaction Conditions | 200µg/ml; 10h |
Applications | Uridine reduced hepatocyte apoptosis induced by CCl4, significantly decreased the expression of Caspase-3 and Bax, and upregulated the expression of Bcl-2. |
| Animal experiment [1]: | |
Animal models | C57BL/6J mice |
Preparation Method | The establishment of the experimental mouse model was approved by the Animal Ethics Committee of the Intervention and Cell Therapy Center of Peking University Shenzhen Hospital. 30 healthy C57BL/6J mice were chosen (6–7 weeks old, weighing between 19 ± 2g) and randomly divided them into control group, model group and Uridine treatment group. Model group: CCl4 was mixed with olive oil into a 10% oily solvent, the mice from the model group were injected intraperitoneally with the mixed solution at 0.6μl/g twice per week for 8 weeks; Control group: the C57BL/6J mice were injected intraperitoneally with the same volume of olive oil at the same time point (as negative control); Uridine treatment group, the mice were given Uridine by drinking water (10–20mg/kg) for 6 weeks. Twenty‐four hours after the last injection, the eyeballs of experimental animals were removed and blood was collected. The mice were anaesthetized and perfused with saline. The liver tissues were collected for a series of biological analyses. |
Dosage form | 10-20mg/kg/day for 6 weeks; oral |
Applications | Uridine alleviated liver fibrosis in mice with CCl4-induced liver fibrosis model, and inhibited the expression of pro-inflammatory cytokines and the activation of the NF-κB signaling pathway. |
References: | |
| Cas No. | 58-96-8 | SDF | |
| Synonyms | NSC 20256, 1-β-D-Ribofuranosyluracil, Uracil-1-β-D-ribofuranoside, β-Uridine | ||
| Chemical Name | 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione | ||
| Canonical SMILES | C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O | ||
| Formula | C9H12N2O6 | M.Wt | 244.2 |
| Solubility | ≥ 71.4mg/mL in DMSO | Storage | Store at 4°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 4.095 mL | 20.475 mL | 40.95 mL |
| 5 mM | 819 μL | 4.095 mL | 8.19 mL |
| 10 mM | 409.5 μL | 2.0475 mL | 4.095 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 14 reference(s) in Google Scholar.)